News | FDA | November 22, 2023

Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT marketLun

 Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT marketLun

November 22, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 3D Breast Tomosynthesis (DBT) AI solution, Lunit INSIGHT DBT. This approval signifies a major step forward in the fight against breast cancer, enabling Lunit to make a full-fledged entry into the US breast screening market. 

Lunit INSIGHT DBT is an AI algorithm engineered to analyze 3D images generated by DBT equipment. DBT imaging offers a faster and more accurate breast cancer diagnosis compared to traditional 2D mammography screenings. 

With DBT's capability to provide more precise breast cancer examinations, the demand for this technology is high, especially among advanced medical institutions in the US, which accounts for over 64% of the global demand for DBT. As of November 2023, 88% of the total 8,850 facilities in the US certified by the Mammography Quality Standards Act and Program (MQSA) are certified units with DBT.[1] 

"The US is the biggest player in the global breast screening market, accounting for up to 40% of the market share. More than 40 million mammography screenings are reported in the US annually," said Brandon Suh, CEO of Lunit. "Given this substantial market influence, achieving FDA clearance for Lunit INSIGHT DBT not only solidifies our presence in the largest market but also marks a significant milestone in our mission to revolutionize breast cancer diagnosis and, ultimately, save more lives." 

With this latest FDA clearance, Lunit continues its journey to bring groundbreaking AI breast imaging to the forefront of cancer diagnosis, promising a future where early detection and treatment of breast cancer becomes more accessible and accurate. 

This FDA clearance follows Lunit's previous achievements in November 2021, when it received FDA clearance for its chest X-ray triage solution 'Lunit INSIGHT CXR Triage' and for its AI-powered mammography analysis solution 'Lunit INSIGHT MMG.' In addition, Lunit INSIGHT DBT has been cleared for Europe by being CE-marked under Europe's latest Medical Device Regulation (EU MDR) since March 2023. 

For more information: https://www.lunit.io/en 

 

Reference: 

[1] MQSA National Statistics: https://www.fda.gov/radiation-emitting-products/mqsa-insights/mqsa-national-statistics 

 

Find more RSNA23 conference coverage here


Related Content

News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
Feature | HIMSS | Christine Book

February 22, 2024 — With just weeks to go before HIMSS 2024, the Global Conference and Exhibition of the Healthcare ...

Time February 22, 2024
arrow
News | Artificial Intelligence

February 22, 2024 — Hartford HealthCare has announced the unveiling of its Center for AI Innovation in Healthcare ...

Time February 21, 2024
arrow
Videos | Information Technology

Industry trade shows and conferences seem to be making their comeback in 2024. And the Healthcare Information and ...

Time February 21, 2024
arrow
News | Computed Tomography (CT)

February 20, 2024 — Ultrahigh-spatial-resolution photon-counting detector CT improved assessment of coronary artery ...

Time February 20, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
Sponsored Content | Videos | Enterprise Imaging

Clinicians and referring physicians need fast, secure access to both patient data and their diagnostic or viewing tool ...

Time February 15, 2024
arrow
News | SPECT Imaging

February 15, 2024 — According to a release issued by the U.S. Food and Drug Administration (FDA), Philips is recalling ...

Time February 15, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
Subscribe Now